Track topics on Twitter Track topics that are important to you
Hancock, MD, Aug. 01, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, held its first investor conference for medical professionals in Maryland.
Dr. Ralph Salvagno, CEO of Petlife Pharmaceuticals, presented an introduction to Petlife’s “Escozine for PetsTM”, a patented, polarized bio-active peptide extracted from the Blue Scorpion (Rhopularus Princeps).
“It was a wonderful opportunity to present Petlife Pharmaceuticals to my medical colleagues. The turnout was great and I am very pleased at the reception to our investment opportunity. Based upon my own research and talking to scientists , veterinarians and pet owners I am confident that we are providing a solution to a unmet need in Veterinary Oncology. What better audience is there to challenge my confidence… the toughest of audiences …my own medical colleagues. The people who have the medical background to evaluate our science and the comfort to challenge a colleague in their beliefs and commitment are the people that I invited to kick off our first Investor Conference. I’m pleased that we were able to engage in serious and successful discussions about how Petlife Pharmaceuticals plans to change the paradigm of treatment in the care of our companion animals afflicted with cancer. Medical professionals also have the business acumen to evaluate the financial part of our investment offering as well and were presented our 506 Private Placement Memorandum (available only to accredited investors ) for their consideration.” Concluding the conference, Dr. Salvagno stated “ The reception of my colleagues to our Company and our investment opportunity has left me even more confident that Petlife is on to something big”.
Petlife plans to participate in the San Francisco Money Show: August 23-25, 2016.
Petlife’s 506 Private Placement Memorandum is available only to accredited investors.
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.
PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets -- Escozine for Pets™. It is based on the same patented 'Escozine for Humans' formula that has been sold by affiliated companies worldwide in 40 countries. Escozine for Pets™ uses a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.
PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology -- with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.
Investor Relations: Invicto Group email@example.com 800-928-7462 Ext. 801NEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...